Overall survival for subgroup age 60 years and older glioblastoma · high‐grade glioma
Hypofractionated radiotherapy showed no clear difference in overall survival for subgroup aged ≥ 60 years glioblastoma compared with daily conventionally fractionated radiotherapy (high certainty).
1 finding from 1 review
Contamination with fluorescent · Preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff
It is very uncertain whether procedures: single‐step doffing changes fluorescent contamination compared with centers (very low certainty).
1 finding from 1 review
Bacterial contamination · Preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff
It is very uncertain whether procedures: single‐step doffing changes bacterial contamination compared with centers (very low certainty).
1 finding from 1 review
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review
Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Comparison: outcome · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Iron supplementation versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in iron supplementation versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Rhodiola crenulata versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in rhodiola crenulata versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Comparison: outcome · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention may leads to lower ginkgo biloba versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + ginkgo biloba versus ginkgo biloba: risk of AMS · participants at risk of high altitude illness
The intervention may leads to lower acetazolamide + ginkgo biloba versus ginkgo biloba: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide versus medroxyprogesterone: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk… (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review